Literature DB >> 20685943

Non-invasive characterization of the area-at-risk using magnetic resonance imaging in chronic ischaemia.

Ming Wu1, Jan D'hooge, Javier Ganame, Vesselina Ferferieva, Karin R Sipido, Frederik Maes, Steven Dymarkowski, Jan Bogaert, Frank E Rademakers, Piet Claus.   

Abstract

AIMS: we investigated the performance of quantitative stress perfusion magnetic resonance imaging (MRI) as a basis for identifying and characterizing the area-at-risk subtending a chronic coronary artery (CA) stenosis. METHODS AND
RESULTS: pigs underwent a percutaneous copper-coated stent implantation in the circumflex CA (n = 11) or a sham operation (n = 5). After 6 weeks, angiography and MRI were performed including cine (rest, low- and high-dose dobutamine stress), dual-bolus first-pass perfusion (rest and adenosine stress), and contrast-enhanced imaging to quantify myocardial infarction (MI). Myocardial blood flow (MBF) was quantified based on Fermi-model deconvolution and compared with microsphere measurements. On the basis of Evan's blue staining, MBF thresholds to define the area-at-risk were determined by receiver-operating characteristic (ROC) analysis. CA stenosis was 94 ± 7% and infarct size (IS) 7.3 ± 3.1% of left ventricular mass. Segmental thresholds of hyperaemic MBF yielded the best performance for detecting area-at-risk. There was a good correlation between MRI and microsphere perfusion (r(2) = 0.84, P < .0001). The area-at-risk presented a mixed substrate of non-infarcted (non-MI), <50% infarcted (MI+), and >50% infarcted (MI++) segments. MBF was reduced in at-risk vs. remote segments at rest (non-MI, 0.50 ± 0.21; MI+, 0.47 ± 0.14; MI++, 0.42 ± 0.14; remote, 0.84 ± 0.25 mL/min/g) and during stress (non-MI, 0.69 ± 0.09; MI+, 0.66 ± 0.14; MI++, 0.51 ± 0.11; remote, 1.70 ± 0.36 mL/min/g). Segmental wall thickening showed different responses to stress (remote, progressive increase during incremental stress; non-MI, increase at low-dose and discontinued at high-dose; MI+, initial increase and decrease at high-dose; MI++, progressive decrease).
CONCLUSION: quantitative hyperaemic perfusion MRI accurately defines segments in the area-at-risk in chronic ischaemia, which present with different functional response to stress related to segmental IS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685943     DOI: 10.1093/cvr/cvq257

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  5 in total

1.  The emerging role of magnetic resonance imaging and multidetector computed tomography in the diagnosis of dilated cardiomyopathy.

Authors:  Massimo Slavich; Anca Florian; Jan Bogaert
Journal:  Insights Imaging       Date:  2011-05-19

2.  Cyclosporine A reduces microvascular obstruction and preserves left ventricular function deterioration following myocardial ischemia and reperfusion.

Authors:  Jaroslaw Zalewski; Piet Claus; Jan Bogaert; Nina Vanden Driessche; Ronald B Driesen; Diogo T Galan; Karin R Sipido; Piotr Buszman; Krzysztof Milewski; Frans Van de Werf
Journal:  Basic Res Cardiol       Date:  2015-02-27       Impact factor: 17.165

3.  Pyridoxamine improves survival and limits cardiac dysfunction after MI.

Authors:  Dorien Deluyker; Vesselina Ferferieva; Ronald B Driesen; Maxim Verboven; Ivo Lambrichts; Virginie Bito
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

Review 4.  Ventricular Arrhythmias in Ischemic Cardiomyopathy-New Avenues for Mechanism-Guided Treatment.

Authors:  Matthew Amoni; Eef Dries; Sebastian Ingelaere; Dylan Vermoortele; H Llewelyn Roderick; Piet Claus; Rik Willems; Karin R Sipido
Journal:  Cells       Date:  2021-10-01       Impact factor: 6.600

5.  Preclinical evaluation of carbon-11 and fluorine-18 sulfonamide derivatives for in vivo radiolabeling of erythrocytes.

Authors:  Olivier Gheysens; Vamsidhar Akurathi; Rufael Chekol; Tom Dresselaers; Sofie Celen; Michel Koole; Dieter Dauwe; Bernard J Cleynhens; Piet Claus; Stefan Janssens; Alfons M Verbruggen; Johan Nuyts; Uwe Himmelreich; Guy M Bormans
Journal:  EJNMMI Res       Date:  2013-01-15       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.